OSTEODISTROPHY IN PATIENTS WITH CHRONIC KIDNEY DISEASE

DOI: 10.22138/2500-0918-2018-15-3-362-371

M.V. Mirgorodskaja, T.V. Zhdanova, T.V. Zueva, E.V. Kuznecova

Ural State Medical University, Yekaterinburg, Russian Federation

Abstract. Relevance. Internationally recognized classification of renal osteodystrophy was proposed in 2006, Moe S., Drueke T. It is based on: the turnover, mineralization and bone volume. Since in the presence of renal osteodystrophy not only changes the density of the bone tissue, but also its microarchitectonics, densitometry and retgenologicheskie research methods have significant limitations for the assessment of bone and fracture risk. The only reliable method of determining the shape of renal osteodystrophy is a histo-morphological study. However, biopsy is not a routine research method. With a low information content of non-invasive diagnostic methods, the true prevalence of different forms of renal osteodystrophy is unknown. The least data on changes in bones in patients with early stages of CKD. Previously it was believed that before the development of gross metabolic disorders, in the bone is not a specific change. But recently, when the processes of changing bone tissue ceased to be regarded as exclusively secondary. According to recent research, it became clear that adeninamic bone disease in patients with mild to moderate CKD is the predominant form. Osteodystrophy with high turnover develops laterwith the emergence of skeletal resistance to parathyroid hormone. The study of the mechanisms of development and diagnosis of renal osteodystrophy allows a differentiated approach to the treatment and evaluation of bone fracture risk in patients with CKD. The research of this section is extremely promising.

Keywords: renal osteodystrophy, chronic kidney disease

Received 02.03.2018

For citation:
Mirgorodskaja M.V., Zhdanova T.V., Zueva T.V., Kuznecova E.V. Оsteodistrophy in patients with chronic kidney disease. Vestn. Ural. Med. Akad. Nauki. = Journal of Ural Medical Academic Science. 2018, Vol. 15, no. 3, pp. 362–371. DOI: 10.22138/2500-0918-2018-15-3-362-371 (In Russ)

REFERENCES
1. Vetchinnikova O.N. Kidney transplantation and bone disease: risk factors of development and diagnostics. Russian Journal of Transplantology and Artificial Organs. 2017;19(1):111-121. (in Russian) DOI:10.15825/1995-1191-2017-1-111-121.
2. Iwasaki Y., Kazama J.J., Fukagawa M. Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease. Bio Med Research. 2017; Article ID 3485785: Р.11. DOI: 10.1155/2017/3485785.
3. D’Marco L., Bellasi A., Mazzaferro S., Raggi P. Vascular calcification, bone and mineral metabolism after kidney transplantation. World J. Transplant. 2015; 24; 5 (4): 222–230. PMCID: PMC4689932. DOI: 10.5500/wjt.v5.i4.222.
4. Moe S., Drueke T., Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy. Kidney Disease: Improving Global Outcomes (KDIGO). 2006; 69: 1945–1953.
5. Cejka D. Wiener Medizinische Wochenschrift. 2013; 163: Р.403–408.
6. Rozhinskaja L. Ja., Egshajan L. V. Pathology of the osseous system with secondary hyperparathyroidism in patients with terminal stage of chronic kidney disease on hemodialysis. Osteoporosis and Osteopathy.2010; №2: 18-22. (in Russ)
7. Ermolenko V.M., Vetchinnikova O.N., Volgina G.V. et al. Association of Nephrologists. Scientific Society of the Nephrologists of Russia: Mineral and steric disorders in chronic kidney disease. 2015. (in Russ)
8. Dalolioa M., Lucarellaa P., Rampinia G.P., Bulfamanteb S., ldeac A., Graveleauc P., Gaillardc S., Scarone P. Neurosurgical aspects of dialysis-related spinal amyloidosis: Report of three cases and a review of the literature. Neurochirurgie. 2017.63(4):314-319. PMID:28882602. DOI:10.1016/j.neuchi.2016.11.110.
9. Moe S., Drueke T., Cunningham J. et al. Kidney Intern. 2006;69:1945-1953.
10. Davies H.M. Osteitis fibrosa cystica. Proc RSoc Med. 1915; 8:34.
11. Bauer W., Albright F., Aub J.C. A case of osteitis fibrosa cystica (osteomalacia?) with evidence of hyperactivity of the para-thyroid bodies. Metabolic StudyIi. J Clin Invest. 1930;8:229–248.
12. Albright F., Drake T.G., Sulkowitch H.W. Renal osteitis fibrosa cystica. Bull Johns Hopkins Hosp. 1937; 60:377–399.
13. Leonard M.B. A structural approach to skeletal fragility in chronic kidney disease. Semin Nephrol. 2009; 29:133–143. DOI: 10.1016/j.semnephrol.2009.01.006.
14. Jamal S.A., Hayden J.A., Beyene J. Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis. Amer. J. Kidney. 2007. 49: 674–681. PMID: 17472850. DOI: 10.1053/j.ajkd.2007.02.264.
15. Brown T.W., Genant H.K., Hattner R.S. et al. Multiple brown tumors in a patient with chronic renal failure and secondary hyperparathyroidism. Amer. J. Roentgenol. 1977. 128:131–134.
16. Salusky I.B., Goodman W.G., Kuizon B.D. et al. Similar predictive value of bone turnover using first and second generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int. 2003;63:1801–1808.DOI: https://doi.org/10.1046/j.1523-1755.2003.00915.x.
17. Karlovich N.V., Komissarov K.S., Gromyko V.N., Mohort T.V., Pilotovich V.S. Renal osteodystrophy: modern approaches to diagnosis and treatment. Medical Journal of the Belarusian State University of Minsk.2007; 1(19):44-48. (in Russ)
18. Lacativa P.G., de Mendonca L.M., de Mattos Patricio Filho P.J. et al. J. Clin. Densitom. 2005; 8 (3): 352—361.
19. Keith M.D., Hruska A. Renal osteodystrophy. Bailliere's Clinical Endocrinology and Metabolism. 1997; 11(1): 165-194.
20. Spasovski G.B., Bervoets A.R., Behets G.J., et al. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Transplant. 2003;18(6):1159-66.
21. Ward M.K., Feest T.G., Ellis H.A., et al. Osteomalacic dialysis osteodystrophy: evidence for a water-borne aetiological agent, probably aluminium. Lancet. 1978;1:841–845.
22. Andreoli S.P., Bergstein J.M., Sherrard D.J. Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis. N Engl J Med. 1984;310:1079–1084.
23. Ott S.M., Maloney N.A., Coburn J.W. et al. The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. N Engl J Med. 1982; 307: 709–713.
24. Coburn J.W. An update on vitamin D as related to nephrology practice. Kidney Int Suppl. 2003:S125–S130.
25. Hernandez J.D., Wesseling K., Salusky I.B. Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy. Semin Dial. 2005;18:290–295.
26. Tilman B. Drueke, Ziad A. Massy, Changing bone patterns with progression of chronic kidney di. Kidney Int. 2016;89: 289–302.
27. Torres A., Lorenzo V., Hernandez D. et al. Bone disease in predialysis, hemodialisis and CAPD patients: Evidence of a better bone response to PTH. Kidney Int 1995; 47: 1434?1442.
28. Borisov A.V., Mordik A.I., Borisova E.V., Ermakova I.P. Diagnostics, prevention and correction of low bone metabolism in hemodialysis (HD) patients. Nephrol and Dial. 2005; 4: 453-457. (in Russ)
29. Martola L., Barany P., Stenvinkel P. Why do dialysis patients develop a heart of stone and bone of china? Blood Purifi cation. 2005; 23:203–210.
30. Bushinsky D.A., Frick K.K. The effects of acid on bone. Curr Opin Nephrol Hypertens. 2000; 9: 369–379.
31. Alikhani M., Alikhani Z., Boyd C. et al. Advanced glycation end-products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone. 2007; 40: 345–353.
32. Avram M.M., Sreedhara R., Fein P. et al. Survival on hemodialysis and peritoneal dialysis over 12 years with emphasis on nutritional parameters. Am J Kidney Dis. 2001; 37: 77–80.
33. Borisov A.V., Mordik A.I., Borisova E.V., Ermakova I.P et al.. Parathyroid function and mineral density of bone tissue in patients with chronic renal failure who are on treatment with programmed hemodialysis. Osteoporosis and Osteopathy. 2004; 1: 6-10. (in Russian)
34. Touam M., Martinez F., Lacour B., et al. Aluminium-induced, reversible microcytic anemia in chronic renal failure: clinical and experimental studies. Clin Nephrol. 1983;19:295–298.
35. Alfrey A.C., LeGendre G.R., Kaehny W.D.. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med. 1976;294: 184–188.
36. Coen G., Mazzaferro S., Ballanti P., et al. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a crosssectional study. Nephrol Dial Transplant. 1996;11:813–819.
37. Barreto F.C., Barreto D.V., Canziani M.E., et al. Association between indoxyl sulfate and bone histomorphometry in pre-dialysis chronic kidney disease patients. J Bras Nefrol. 2014;36:289–296.
38. Miller P.D. Chronic kidney disease and the skeleton. Bone Res. 2014; 2: 14044. PMID:26273531 PMCID:PMC4472138. DOI: 10.1038/boneres.2014.44.
39. Miller P.D. Chronic kidney disease and osteoporosis: evaluation and management. Bonekey Rep.2014;3:542. PMID:24991405. PMCID:PMC4078413. DOI: 10.1038/bonekey.2014.37
40. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney International Supplements. 2017; 7 (1) Pages 1-59.
41. Vervloet M.G., Massy Z.A., Brandenburg V.M., et al. Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. Lancet Diabetes Endocrinol. 2014;2:427–436.
42. Wesseling-Perry K., Osteocyte dysfunction and renal osteodystrophy: not just calcium and phosphorus anymore. Kidney Int. 2017. 91(6):1276-1278. PMID: 28501301. DOI: 10.1016/j.kint.2017.02.026.
43. Mora Palma F.J., Ellis H.A., Cook D.B., et al. Osteomalacia in patients with chronic renal failure before dialysis or transplantation. Q J Med. 1983;52: 332–348.
44.Sabbagh Y., Graciolli F.G., O’Brien S., et al. Repression of osteocyte Wnt/ beta-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner R 2012;27:1757–1772.
45. Miller P.D. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Curr. Osteoporos. Rep. 2005; 3(1):5—12. PMID: 16036095.
46. Vetchinina O.N., Gubkina V.A., Mylov N.M., Rubin M.P Comparative information of the densitometry of the peripheral and axial skeet in the diagnosis of osteopenic syndrome in patients with chronic renal insufficiency. Osteoporosis and osteopathy. 2005;1:7-11. (in Russian)

Authors
Maria V. Mirgorodskaja
Assistant of the department of internal medicine propaedeutics
anymashka.1812@gmail.com

Tatyana V. Zhdanova
Dr. Sci. (Med.), Professor, Head of the Department of Internal Medicine Propaedeutics
nephrocentre@inbox.ru

Tatyana V. Zueva
Cand. Sci. (Med.), Associate Professor of the Department of Internal Medicine Propaedeutics
zt_2008@mail.ru

Elena V. Kuznecova
Cand. Sci. (Med.), Associate Professor, Associate Professor of the Department of Internal Medicine Propaedeutics
aliska@k66.ru

Ural State Medical University
Repin str. 3, Yekaterinburg, Russian Federation, 620028
usma@usma.ru